Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer

Modern Pathology

Volumn 17, Issue 4, 2004, Pages 440-448

  Toledo, Gemma ^a,b   Sola, Jesús Javier ^a   Lozano, Maria Dolores ^a   Soria, Elena ^a   Pardo, Javier ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Apoptosis; FHIT; Flow cytometry; Immunohistochemistry; Ki 67; Loss of heterozygosity; Non small cell lung carcinoma

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; DNA; FRAGILE HISTIDINE TRIAD PROTEIN; MYC PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; ACID ANHYDRIDE HYDROLASE; KI 67 ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; FLOW CYTOMETRY; GENE LOCUS; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; NICK END LABELING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; CANCER STAGING; CELL DIVISION; DISEASE FREE SURVIVAL; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION;

ACID ANHYDRIDE HYDROLASES; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; KI-67 ANTIGEN; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 4644304354     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800081     Document Type: Article

References (48)

1. Black RJ, Bray F, Ferlay J, et al. Cancer Incidence and Mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997;33:1075-1107.
2. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
3. Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3pl4.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-597.
4. Brenner C, Bieganowski P, Pace HC, et al. The histidine triad superfamily of nucleotide-binding proteins. J Cell Physiol 1999;181:179-187.
5. Fong KM, Biesterveld EJ, Virmani A, et al. FHIT and FRA3B 3pl4.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 1997;57:2256-2267.
6. Fullwood P, Marchini S, Rader JS, et al. Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer. Cancer Res 1999;55:4662-4667.
7. Guo Z, Wu F, Asplund A, et al. Analysis of intratumoral heterogeneity of chromosome 3p deletions and genetic evidence of polyclonal origin of cervical squamous carcinoma. Mod Pathol 2001;14:54-61.
8. Kastury K, Baffa R, Druck T, et al. Potential gastrointestinal tumor suppressor locus at the 3pl4.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res 1996;56:978-983.
9. Maitra A, Wistuba II, Washington C, et al. High resolution chromosome 3p allelotyping of breast carcinomas and precursors lesions demonstrates frequent loss of heterozigosity and a discontinuous pattern of allele loss. Am J Pathol 2001;159:119-130.
10. Negrini M, Monaco C, Vorechovsky I, et al. The FHIT gene at 3pl4.2 is abnormal in breast carcinomas. Cancer Res 1996;56:3173-3179.
11. Sozzi G, Veronese ML, Negrini M, et al. The FHIT gene at 3pl4.2 is abnormal in lung cancer. Cell 1996;85:17-26.
12. Sozzi G, Sard L, De Gregorio L, et al. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 1997;57:2121-2123.
13. Sozzi G, Tornielli S, Tagliabue E, et al. Absence of FHIT protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res 1997;57:5207-5212.
14. Velickovic M, Delahunt B, Grebe SK. LOH at 3pl4.2 in CCRC (clear cell renal carcinoma) is an early event and is highly localized to the FHIT gene locus. Cancer Res 1999;59:1323-1326.
15. Virgilio L, Schuster M, Gollin SM, et al. FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 1996;93:9770-9775.
16. Wu R, Connolly DC, Dunn RL, et al. Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cells. J Natl Cancer Inst 2000;92:338-344.
17. Burke L, Khan MA, Freedman AN, et al. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res 1998;58:2533-2536.
18. Garinis GA, Gorgoulis VG, Mariatos G, et al. Assosiation of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs). J Pathol 2001;193:55-65.
19. Marchetti A, Pellegrini S, Bertacca G, et al. FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas: correlations with clinicopathological data and K-ras mutations. J Pathol 1998;184:240-246.
20. Pavelic K, Krizanac S, Cacev T, et al. Aberration of FHIT gene is associated with increased tumor proliferation and decreased apoptosis-clinical evidence in lung and head and neck carcinomas. Mol Med 2001;7:442-453.
21. Sozzi G, Musso K, Ratcliffe C, et al. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res 1999;5:2689-2692.
22. Tokuchi Y, Kobayashi Y, Hayashi S, et al. Abnormal FHIT transcripts found in both cancer and normal lung tissue. Genes Chromosomes Cancer 1999;24:105-111.
23. Tseng JE, Kemp BL, Khuri FR, et al. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 1999;59:4798-4803.
24. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000;60:1949-1960.
25. Siprashvili Z, Sozzi G, Barnes LD, et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997;94:13771-13776.
26. Ji L, Fang B, Yen N, et al. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999;59:3333-3339.
27. Sard L, Accornero P, Tornielli S, et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 1999;96:8489-8492.
28. Capuzzi D, Santoro E, Hauck WW, et al. FHIT expression in gastric adenocarcinoma: correlation with disease stage and survival. Cancer 2000;88:24-34.
29. Eyzaguirre EJ, Miettinen M, Norris BA, et al. Different immunohistochemical patterns of FHIT protein expression in renal neoplasms. Mod Pathol 1999;12:979-983.
30. Lee JI, Soria JC, Hassan K, et al. Loss of FHIT expression is a predictor of poor outcome in tongue cancer. Cancer Res 2001;61:837-841.
31. Ramp U, Caliskan E, Ebert T, et al. FHIT expression in clear cell renal carcinomas: versatility of protein levels and correlation with survival. J Pathol 2002;196:430-36.
32. Shimada Y, Sato F, Watanabe G, et al. Loss of fragile histidine triad gene expression is associated with progression of esophageal squamous cell carcinoma, but not with the patient's prognosis and smoking history. Cancer 2000;89:5-11.
33. Tomizawa Y, Nakajima T, Kohno T, et al. Clinicopathological significance of FHIT protein expression in stage I non-small cell lung carcinoma. Cancer Res 1998;58:5478-5483.
34. Travis WD, Colby TV, Corrin B, et al. Histological classification of lung and pleural tumours. In: World Health Organization (WHO), Travis WD (ed). Histological Typing of Lung and Pleural Tumors, Vol. 1, 3rd edn. Heidelberg, Germany: Springer Verlag, 1999, pp 21-24.
35. Vindelöv L, Christensen I, Nissen N. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983;3:323-327.
36. Panizo-Santos A, Sola JJ, Pardo-Mindán FJ, et al. Angiotensin converting enzyme inhibition prevents polyploidization of cardiomyocytes in spontaneously hypertensive rats with left ventricular hypertrophy. J Pathol 1995;177:431-437.
37. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific binding of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
38. Geradts J, Fong KM, Zimmerman PV, et al. Loss of FHIT expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features. Br J Cancer 2000;82:1191-1197.
39. Otterson GA, Xiao GH, Geradts J, et al. Protein expression and functional analysis of the FHIT gene in human tumor cell. J Natl Cancer Inst 1998;90:426-32.
40. Sozzi G, Pastorino U, Moiraghi L, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998;58:5032-5037.
41. Baffa R, Veronese ML, Santoro R, et al. Loss of FHIT expression in gastric carcinoma. Cancer Res 1998;58:4708-4714.
42. Baffa R, Cornelia L, Vecchione A, et al. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am J Pathol 2000;156:419-24.
43. Croce CM, Sozzi G, Huebner K. Role of FHIT in human cancer. J Clin Oncol 1999;17:1618-1624.
44. Michael D, Rajewsky MF. Induction the common fragile site FRA3B does not affect FHIT expression. Oncogene 2001;20:1798-1801.
45. Sutherland GR, Richards RI. The molecular basis of fragile sites in human chromosomes. Curr Opin Genet Dev 1995;5:323-327.
46. Roz L, Gramegna M, Ishii H, et al. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci USA 2002;99:3615-3620.
47. Vartanian A, Prudovsky I, Suzuki H, et al. Opposite effects of cell differentiation and apoptosis on Ap3A/Ap4A ratio in human cell cultures. FEES Lett 1997;415:160-162.
48. Huebner K, Garrison PN, Barnes LD, et al. The role of the FHIT/FRA3B locus in cancer. Annu Rev Genet 1998;32:7-31.